Ginsenoside Rg1 (Rg1) (Rg1)

Ginsenoside Rg1 is a major bioactive dammarane-type tetracyclic triterpenoid saponin primarily derived from the roots of Panax ginseng (PubChem CID 441923). It is distinguished by its polypharmacological profile, functioning as a functional ligand for various receptors and enzymes rather than a single target (NIH, 2025). Rg1 exhibits potent neuroprotective, anti-inflammatory, and cardioprotective properties by modulating key signaling pathways such as PI3K/Akt, Nrf2/HO-1, and NF-kappaB (Frontiers in Pharmacology, 2025). It also acts as a phytoestrogen and a glucocorticoid receptor agonist, contributing to its diverse therapeutic effects in neurodegenerative diseases like Alzheimer's and Parkinson's, as well as metabolic disorders (NIH, 2022). Despite its broad potential, Rg1 faces challenges such as low oral bioavailability and limited penetration of the blood-brain barrier (NIH, 2026). Its multi-target nature allows it to address complex disease pathologies by simultaneously influencing oxidative stress, apoptosis, and inflammatory responses (ResearchGate, 2025). Furthermore, it has been shown to inhibit acetylcholinesterase and BACE1, providing a dual-action approach for cognitive enhancement in dementia (NIH, 2022).

Other names

Panaxoside Rg1Sanchinoside C1Ginsenoside A2G-Rg1

Ginsenoside Rg1 acts as a multi-target modulator that activates the glucocorticoid and estrogen receptors, inhibits acetylcholinesterase and BACE1, and regulates the PI3K/Akt, Nrf2/HO-1, and NF-kappaB signaling pathways to exert neuroprotective, anti-inflammatory, and antioxidant effects (NIH, 2022; Frontiers in Pharmacology, 2025).